Abstract: Recently, 2019 novel coronavirus variant strain Omicron BA.2 subtype is in a global pandemic and of great danger to people’s safety. Tumor patients are in a state of immune imbalance due to the disease itself or treatment, so they are more likely to suffer from coronavirus disease 2019 (COVID-19), and the mortality after infection is higher than normal people. Immune status differs between tumor patients and normal population after virus infection, which includes two aspects: one is the unregulated excessive release of various cytokines, and the other is the subsequent weakness of humoral and cellular immunity. Therefore, the anti-tumor treatment strategy should be adjusted accordingly. A review of the relevant research progress is presented to provide reference for the treatment of this special population.